Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET
Company Participants
Todd Tushla - VP, IR
Kevin Gorman - CEO
Matt Abernethy - CFO
Eiry Roberts - Chief Medical Officer
Eric Benevich - Chief Commercial Officer
Kyle Gano - Chief Business Development & Strategy Officer
Conference Call Participants
Paul Matteis - Stifel
Tazeen Ahmad - Bank of America
Anupam Rama - JPMorgan
Phil Nadeau - TD Cowen
Jay Olson - Oppenheimer
Leon Wang - Barclays
Marc Goodman - Leerink
Brian Abrahams - RBC Capital Markets
Brian Skorney - Baird
Jeff Hung - Morgan Stanley
Myles Minter - William Blair
Danielle Brill - Raymond James
Evan Seigerman - BMO
Laura Chico - Wedbush Securities
Sumant Kulkarni - Canaccord
David Amsellem - Piper Sandler
Ash Verma - UBS
Yatin Suneja - Guggenheim
Uy Ear - Mizuho
Operator
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Second Quarter Results. [Operator Instructions] It is now my pleasure to turn today's program over to Todd Tushla, Vice President of Investor Relations.
Todd Tushla
Good morning, and welcome to Neurocrine's second quarter 2023 earnings call. Today, I'm joined by Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.
During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks, we will jump into Q&A.
With that, I'll turn the call over to Kevin Gorman.
Kevin Gorman
Thank you, Todd, and good morning, everyone. It's a pleasure to be here this morning. We've had a very strong first half of the year, as you can see from our press release this morning, we are raising our guidance. So what was previously the high end of the range is now the bottom of the range, very strong performance and very proud of our commercial team out there with INGREZZA.
We're now set up for a really exciting second half of the year. We have multiple readouts coming from our pipeline, led by our PDUFA date for INGREZZA and the Chorea associated with Huntington. We have a Focal Onset Seizure and data coming out, Anhedonia - data coming out. And last but not least at all, is the CAH studies, both in the adult and in the pediatric population, and Eiry is going to have a lot more to say about that a little later, and we'll also be taking your questions on that. So quite a bit going on here. It's all been very nice thus far. So I'm really looking for the second half of the year. And right now, I'm going to turn it over to Matt.